Verastem, Inc. announced the initiation of a rolling submission of a New Drug Application (NDA) to the FDA for Accelerated Approval of the combination of avutometinib and defactinib for patients with recurrent KRAS mutant low-grade serious ovarian cancer (LGSOC).